BI 1181181

Drug Profile

BI 1181181

Alternative Names: BI-1181181; VTP-37948

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim; Vitae Pharmaceuticals
  • Developer Boehringer Ingelheim
  • Class Nootropics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 07 Apr 2015 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in Belgium (PO)
  • 01 Apr 2015 Discontinued - Phase-I for Alzheimer's disease (In the elderly, In volunteers, In adults) in Germany (PO)
  • 01 Apr 2015 Boehringer Ingelheim terminates a phase I trial for Alzheimer's disease (In volunteers, In adults, In the elderly) in Germany (NCT02254161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top